High Purity 99% Liraglutide powder CAS 204656-20-2

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates secretion. 

Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
It acts in a glucose-dependent manner, meaning it will stimulate secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.

Certification 

Function:

common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insu.lin secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
4. Liraglutide lowers blood triglyceride levels.

Carcinogenicity, Category 2

Reproductive toxicity, Category 2

no data available

Packing and shipping:

Before-sale service, after sale technical consultancy service.

 6. How to place order online?